Medtronic (NYSE:MDT – Get Free Report) and IRIDEX (NASDAQ:IRIX – Get Free Report) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, valuation, risk, analyst recommendations and dividends.
Valuation and Earnings
This table compares Medtronic and IRIDEX”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Medtronic | $36.36 billion | 3.54 | $4.80 billion | $4.06 | 24.82 |
| IRIDEX | $52.67 million | 0.17 | -$4.44 million | ($0.20) | -2.50 |
Medtronic has higher revenue and earnings than IRIDEX. IRIDEX is trading at a lower price-to-earnings ratio than Medtronic, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Medtronic has a beta of 0.56, suggesting that its share price is 44% less volatile than the S&P 500. Comparatively, IRIDEX has a beta of 0.64, suggesting that its share price is 36% less volatile than the S&P 500.
Analyst Ratings
This is a summary of current recommendations and price targets for Medtronic and IRIDEX, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Medtronic | 1 | 8 | 18 | 0 | 2.63 |
| IRIDEX | 1 | 0 | 1 | 0 | 2.00 |
Medtronic currently has a consensus target price of $103.75, suggesting a potential upside of 2.97%. IRIDEX has a consensus target price of $3.00, suggesting a potential upside of 500.00%. Given IRIDEX’s higher probable upside, analysts plainly believe IRIDEX is more favorable than Medtronic.
Profitability
This table compares Medtronic and IRIDEX’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Medtronic | 13.93% | 14.78% | 7.97% |
| IRIDEX | -6.85% | N/A | -11.96% |
Insider & Institutional Ownership
82.1% of Medtronic shares are owned by institutional investors. Comparatively, 20.1% of IRIDEX shares are owned by institutional investors. 0.3% of Medtronic shares are owned by insiders. Comparatively, 8.6% of IRIDEX shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Summary
Medtronic beats IRIDEX on 10 of the 13 factors compared between the two stocks.
About Medtronic
Medtronic plc is a medical technology company that develops and manufactures devices and therapies for a range of health conditions. Its products include pacemakers and defibrillators, heart valves, surgical technologies, neurostimulation devices, and insulin pumps and other diabetes-management products. The company was founded in Minneapolis in 1949 by Earl Bakken and Palmer Hermundslie as a medical equipment repair business. It has since grown into a global company serving patients and health care providers in more than 150 countries.
About IRIDEX
IRIDEX Corporation develops, manufactures and markets laser-based medical systems and related delivery devices for eye-care professionals. Its products are used to treat retinal diseases and glaucoma, including through laser procedures designed to preserve or improve vision. The company’s offerings include ophthalmic laser systems such as the Cyclo G6 glaucoma laser system and IQ-series photocoagulators, along with treatment-delivery devices and technologies including MicroPulse laser therapy. IRIDEX was founded in 1989 and serves customers internationally through direct sales and distribution partners.
Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.
